Ondansetron Eignapharma

Ondansetron, the active ingredient in Ondansetron Eignapharma, is a 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It helps prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in adult patients.

GNH USA supplies Ondansetron Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on serotonin‑mediated pathways that trigger emesis, providing anti‑emetic protection in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: prevents and controls nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: reduces nausea and vomiting associated with cancer radiation treatments. - Post‑operative nausea and vomiting: helps avoid nausea and vomiting after surgical procedures.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Serotonin syndrome: agitation, hyperreflexia, fever when combined with serotonergic agents.

When using Ondansetron, consider the following safety measures.

- Cardiac monitoring: assess QT interval in patients with known cardiac disease. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before administration. - Drug interactions: review concomitant medications that may affect cardiac rhythm. - Pregnancy: use only if potential benefit justifies potential risk. - Lactation: weigh benefits against possible infant exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ondansetron may interact with several drug classes, requiring attention to interaction severity.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmics (e.g., amiodarone, sotalol): increase risk of QT prolongation. - Serotonergic agents (e.g., SSRIs, MAOIs): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., tramadol): potential alteration of efficacy. - Anticholinergic drugs: may reduce anti‑emetic effectiveness.